In renal cell carcinoma (RCC), continued advances in targeted therapy and immunotherapy have ushered patients with advanced disease into an era of long-term survival and chronic disease management. However, important clinical challenges remain, including optimizing adjuvant treatment for high-risk patients after surgery, selecting effective therapies following immunotherapy resistance, and developing multidisciplinary models for comprehensive care throughout the disease course.

In recent years, the perioperative management of muscle-invasive bladder cancer (MIBC) has undergone rapid transformation. The emergence of immunotherapy, antibody-drug conjugates (ADCs), and precision biomarker-driven treatment has fundamentally reshaped the therapeutic landscape.

The 2026 Annual Meeting of the Chinese Urological Association (CUDA) was held in Zhengzhou from June 11–14, 2026. As one of China's most influential national academic meetings in urology, this year's conference adopted the theme "Collaboration and Innovation", bringing together leading domestic and international experts to discuss advances in minimally invasive surgery, robotic technology, precision medicine, and multidisciplinary cancer care, while promoting high-quality specialty development and the translation of scientific advances into clinical practice.

The 2026 Annual Meeting of the Chinese Urological Association (CUDA) was held in Zhengzhou under the theme "Collaboration and Innovation." The conference focused on key topics including precision diagnosis and treatment of urologic diseases, comprehensive cancer management, and multidisciplinary team (MDT) care, showcasing China's latest advances in technological innovation and the standardization of clinical practice.

The 2026 Annual Meeting of the Chinese Urological Doctor Association (CUDA 2026) was held in Zhengzhou, Henan, from June 11 to 14. Prof. Xingyuan Xiao of Zhongnan Hospital of Wuhan University has long been engaged in the clinical management and research of urologic diseases, with extensive experience in integrating traditional Chinese medicine (TCM) and Western medicine for urologic cancers and treatment-related complications.

The 2026 Annual Meeting of the Chinese Urological Doctor Association (CUDA 2026) was held in Zhengzhou from June 11 to 14. As one of China’s most influential national academic meetings in urology, this year’s congress highlighted cutting-edge developments in robotic surgery, AI-assisted diagnosis and treatment, precision medicine, and minimally invasive technologies, promoting clinical translation and innovation in urologic care.